Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset Alzheimer's disease in the finnish population

Dementia and Geriatric Cognitive Disorders

Volumn 22, Issue 5-6, 2006, Pages 449-453

  Koivisto, Anne Maria ^a,b   Helisalmi, Seppo ^b   Pihlajamäki, Jussi ^a   Hiltunen, Mikko ^b   Koivisto, Keijo ^d   Moilanen, Leena ^a   Kuusisto, Johanna ^a   Helkala, Eeva Liisa ^c   Hänninen, Tuomo ^a,b   Kervinen, Kari ^e   Kesäniemi, Y Antero ^e   Laakso, Markku ^a   Soininen, Hilkka ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b Brain Research Unit   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Central Hospital of South East Bothnia ^*  (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Age of onset; Alzheimer's disease; APOE; Peroxisome proliferator activated receptor ; Polymorphism; PPAR exon 6; PPAR Pro12Ala

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; DNA POLYMORPHISM; EXON; FEMALE; GENE; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; RISK;

AGE OF ONSET; AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; FEMALE; FINLAND; GENOTYPE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 33750908413     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095857     Document Type: Article

References (18)

1. Daw EW, Heath SC, Wijsman EM: Multi-point oligogenic analysis of age-at-onset data with applications to Alzheimer disease pedigrees. Am J Hum Genet 1999;64:839-851.
2. Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broeckhoven C, van Duijn CM: Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 1998;55:964-968.
3. Papassotiropoulos A, Hock C, Nitsch RM: Genetics of interleukin 6: implications for Alzheimer's disease. Neurobiol Aging 2001;22:863-871.
4. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
5. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE: Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000;20:558-567.
6. Lahiri DK: Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene. J Mol Neurosci 2004;23:225-233.
7. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, Heneka MT: Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA 2006;103:443-448.
8. Cock TA, Houten SM, Auwerx J: Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep 2004;5:142-147.
9. Breteler MM: Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000;21:153-160.
10. Sauder S, Kolsch H, Lutjohann D, Schulz A, von Bergmann K, Maier W, Heun R: Influence of peroxisome proliferator-activated receptor gamma gene polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients. J Neural Transm 2005;112:1381-1389.
11. Brune S, Kolsch H, Ptok U, Majores M, Schulz A, Schlosser R, Rao ML, Maier W, Heun R: Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease. J Neural Transm 2003;110:1041-1050.
12. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, Kervinen K, Kesaniemi YA, Riekkinen PJ, Laakso M: Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross-sectional population based-study. BMJ 1997;315:1045-1049.
13. Helkala EL, Koivisto K, Hanninen T, Vanhanen M, Kervinen K, Kuusisto J, Mykkanen L, Kesaniemi YA, Laakso M, Riekkinen P Sr: The association of apolipoprotein E polymorphism with memory: a population based study. Neurosci Lett 1995;191:141-144.
14. American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders, ed 3, revised. Washington, American Psychiatric Association, 1987.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
16. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso M: Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999;84:3708-3712.
17. Ehnholm C, Lukka M, Kuusi T, Nikkila E, Utermann G: Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res 1986;27:227-235.
18. Meirhaeghe A, Amouyel P: Impact of genetic variation of PPARgamma in humans. Mol Genet Metab 2004;83:93-102.